title: [Third-line CPT-11 chemotherapy for gastric cancer cases of non-curative gastrectomy or recurrence].
abstract: BACKGROUND
  There have been few case reports of 3rd-line chemotherapy for gastric cancer. So we reported the results of CPT-11 therapy as the 3rd-line chemotherapy for gastric cancer.
  
  
  METHODS
  549 cases underwent gastrectomy from Jan. 2004 to Aug. 2007 in our hospital. In 76 of these cases, which underwent non-curative resection or evidenced a recurrence until July 2009, were analyzed in this study. CPT -11 3rd-line chemotherapy was administered to 11 cases.
  
  
  RESULTS
  The mean survival time of non-curative or recurrent cases was 16.9 months. Mean survival times of the non-chemotherapy group, the group administered only 1st-line chemotherapy, the group administered until 3rd-line chemotherapy, the group administered 3rd-line chemotherapy were 7.9 , 11.3 , 21.4 and 28.9 months, respectively(p=0.000 ). Adverse effects occurred in 90.9% of 3rd-line CPT-11, however, all cases were categorized in GradeI.
  
  
  CONCLUSIONS
  The group administered 3rd-line chemotherapy survived the longest. It is probably correct to administer 3rd-line chemotherapy, if the patient maintains a good performance status.
authors.affiliation: Department of Surgery, Sapporo Kosei Hospital.
authors.forename: Hideki
authors.initials: H
authors.lastname: Kawamura
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Yokota
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Watarai
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yokota
authors.forename: Toshiro
authors.initials: T
authors.lastname: Tanioka
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Tsunoda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Masuko
authors.forename: Koichi
authors.initials: K
authors.lastname: Tanaka
authors.forename: Hideki
authors.initials: H
authors.lastname: Yamagami
authors.forename: Tsunetake
authors.initials: T
authors.lastname: Hata
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Okada
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ishizu
authors.forename: Yukifumi
authors.initials: Y
authors.lastname: Kondo
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005743:Gastrectomy; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016879:Salvage Therapy; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D000077146:Irinotecan; D002166:Camptothecin